JP7005019B2 - 組織修復のための二重特異性治療用タンパク質 - Google Patents

組織修復のための二重特異性治療用タンパク質 Download PDF

Info

Publication number
JP7005019B2
JP7005019B2 JP2018536700A JP2018536700A JP7005019B2 JP 7005019 B2 JP7005019 B2 JP 7005019B2 JP 2018536700 A JP2018536700 A JP 2018536700A JP 2018536700 A JP2018536700 A JP 2018536700A JP 7005019 B2 JP7005019 B2 JP 7005019B2
Authority
JP
Japan
Prior art keywords
replaced
variant
igf
certain embodiments
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018536700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538356A (ja
JP2018538356A5 (enExample
Inventor
ローラ・ディ・ジェイ・アンティポフ
ショーディー・エシュギ
クリストファー・エム・クッチェンベッカー
ビョルン・エル・ミラード
マシュー・ディ・オンサム
アンドレア・ディ・ニッカーソン
ティモシー・アール・ストウ
ヤン・ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Silver Creek Pharmaceuticals Inc
Original Assignee
Silver Creek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Silver Creek Pharmaceuticals Inc filed Critical Silver Creek Pharmaceuticals Inc
Publication of JP2018538356A publication Critical patent/JP2018538356A/ja
Publication of JP2018538356A5 publication Critical patent/JP2018538356A5/ja
Priority to JP2021159345A priority Critical patent/JP7365715B2/ja
Application granted granted Critical
Publication of JP7005019B2 publication Critical patent/JP7005019B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018536700A 2015-10-02 2016-09-30 組織修復のための二重特異性治療用タンパク質 Active JP7005019B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021159345A JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562236169P 2015-10-02 2015-10-02
US62/236,169 2015-10-02
US201562237889P 2015-10-06 2015-10-06
US62/237,889 2015-10-06
US201662322910P 2016-04-15 2016-04-15
US62/322,910 2016-04-15
PCT/US2016/054744 WO2017059231A1 (en) 2015-10-02 2016-09-30 Bi-specific therapeutic proteins for tissue repair

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021159345A Division JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Publications (3)

Publication Number Publication Date
JP2018538356A JP2018538356A (ja) 2018-12-27
JP2018538356A5 JP2018538356A5 (enExample) 2019-12-26
JP7005019B2 true JP7005019B2 (ja) 2022-02-04

Family

ID=58427983

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018536700A Active JP7005019B2 (ja) 2015-10-02 2016-09-30 組織修復のための二重特異性治療用タンパク質
JP2021159345A Active JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021159345A Active JP7365715B2 (ja) 2015-10-02 2021-09-29 組織修復のための二重特異性治療用タンパク質

Country Status (7)

Country Link
US (6) US10040840B2 (enExample)
EP (2) EP3355907B1 (enExample)
JP (2) JP7005019B2 (enExample)
CN (2) CN108367048B (enExample)
CA (1) CA3000742A1 (enExample)
ES (1) ES2863278T3 (enExample)
WO (1) WO2017059231A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002528A (ja) * 2015-10-02 2022-01-11 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッドSilver Creek Pharmaceuticals, Inc. 組織修復のための二重特異性治療用タンパク質

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞
JP7355326B2 (ja) * 2019-08-05 2023-10-03 デンカ株式会社 経粘膜投与薬剤
CA3152500A1 (en) * 2019-09-06 2021-03-11 Novartis Ag Therapeutic fusion proteins
CN112584507B (zh) 2019-09-30 2022-05-17 华为技术有限公司 一种数据处理方法、装置及存储介质
CN115379850A (zh) 2019-12-24 2022-11-22 裘美娜治疗公司 再生性多肽及其用途
CN111195350A (zh) * 2020-01-15 2020-05-26 重庆大学 IGF1和IGF1Ec24联合在制备促进组织修复与再生的药物中的应用
EP4188410B1 (en) * 2020-07-30 2025-11-05 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for use in the treatment of central nervous system disorders
WO2022263407A2 (en) 2021-06-14 2022-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes
CA3223707A1 (en) 2021-06-21 2022-12-29 Hanadie Yousef Regenerative polypeptides and uses thereof
US20240279359A1 (en) * 2021-06-30 2024-08-22 Silver Creek Pharmaceuticals, Inc. Chimeric proteins for targeted delivery of growth factors to the glomerulus
EP4479417A4 (en) * 2022-02-15 2025-12-10 Silver Creek Pharmaceuticals Inc Chimeric proteins for the treatment of acute radiation syndrome
WO2025207443A1 (en) * 2024-03-25 2025-10-02 Cavalry Biosciences, Inc. Igf-1-related compositions and uses of the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526233A (ja) 2005-01-07 2008-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−ｉ融合ポリペプチドの組み合わせ治療用物質による肥満治療法
JP2013530146A (ja) 2010-05-21 2013-07-25 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL269416A (enExample) 1960-09-21
GB8819826D0 (en) 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1
US5679771A (en) 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
AU660297B2 (en) 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5444045A (en) * 1992-09-17 1995-08-22 Gropep, Pty. Ltd. Method of administering IGF-1, IGF-2, and analogs thereof to birds
JP3664727B2 (ja) * 1994-01-24 2005-06-29 ネオルクス コーポレイション 放射標識したアネキシン
EP0756494A1 (en) 1994-05-24 1997-02-05 Amgen Boulder Inc. Modified insulin-like growth factors
US5780052A (en) 1995-04-24 1998-07-14 Northeastern University Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell
AU2676297A (en) 1996-04-17 1997-11-07 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2331789C (en) 1998-07-13 2013-09-10 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
JP2002535967A (ja) 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2001007059A1 (en) 1999-07-21 2001-02-01 University Of Southern California Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
JP2001251104A (ja) 2000-03-03 2001-09-14 Murata Mfg Co Ltd 非可逆回路素子及び通信機装置
ES2346185T3 (es) 2000-08-29 2010-10-13 Aurogen Incorporated Metodo para tratar el sistema nervioso central mediante la administracion de analogos estructurales de igf.
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
EP1974752B1 (en) 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
AU2008200706B2 (en) 2001-10-16 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7576186B2 (en) 2002-04-23 2009-08-18 Roger Williams Hospital Compositions and methods for stem cell delivery
WO2003103577A2 (en) 2002-06-06 2003-12-18 Tze Chein Wun Novel recombinant anticoagulant proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040213738A1 (en) 2003-03-31 2004-10-28 Susan Croll-Kalish CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity
WO2005033134A2 (en) 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
BRPI0510716A (pt) 2004-05-05 2007-11-20 Merrimack Pharmaceuticals Inc uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
US7511016B2 (en) 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
JP2008510732A (ja) 2004-08-20 2008-04-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム 心臓組織の損傷を処置、予防、阻害、または緩和する方法
JP2008517917A (ja) * 2004-10-21 2008-05-29 アイジーエフ オンコロジー エルエルシー 癌を治療するための毒素および放射性核種結合ｉｇｆ−１受容体リガンド
WO2006076525A2 (en) 2005-01-14 2006-07-20 Cytogen Corporation Combination cancer therapy with anti-psma antibodies
CA2591914C (en) 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
BRPI0519897A2 (pt) 2005-02-23 2009-08-18 Merrimack Pharmaceuticals Inc método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit
US7521211B2 (en) 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
WO2006128125A2 (en) 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007044887A2 (en) 2005-10-11 2007-04-19 Transtarget, Inc. Method for producing a population of homogenous tetravalent bispecific antibodies
DK1960790T3 (en) 2005-12-12 2017-03-06 Mosamedix Bv ANNEXIN DERIVATIVES SUITABLE FOR PREGNANCY FOR TREATMENT AND DIAGNOSIS
US7776816B2 (en) 2006-01-20 2010-08-17 Board Of Regents, The University Of Texas System Preserving hypoxic tissue
JP2009525986A (ja) 2006-02-03 2009-07-16 メディミューン，エルエルシー タンパク質製剤
US7951918B2 (en) 2006-03-17 2011-05-31 Biogen Idec Ma Inc. Stabilized polypeptide compositions
AU2007255419A1 (en) 2006-06-09 2007-12-13 Novartis Ag Stabilized insulin-like growth factor polypeptides
US9187517B2 (en) 2006-11-13 2015-11-17 The Brigham And Women's Hospital, Inc. Methods of promoting cardiac repair using growth factors fused to heparin binding sequences
SE530073C2 (sv) 2007-01-23 2008-02-26 Teknikbolaget K Samuelsson Ab Sprutmunstycksanordning för brandsläckningssystem
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
US8889140B2 (en) 2007-05-31 2014-11-18 Transtarget, Inc. Compositions and methods for tissue repair
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
ES2422007T3 (es) 2007-06-21 2013-09-06 Univ Muenchen Tech Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro
WO2009030720A2 (en) 2007-09-06 2009-03-12 Novozymes Biopharma Dk A/S Process for producing a recombinant protein
CN102057054B (zh) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
KR20110112301A (ko) 2008-11-18 2011-10-12 메리맥 파마슈티컬즈, 인크. 인간 혈청 알부민 링커 및 그 콘쥬게이트
CA2751068A1 (en) * 2009-01-31 2010-08-05 Igf Oncology, Llc Anti-cancer protein-platinum conjugates
RU2511577C2 (ru) 2009-07-22 2014-04-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
WO2011011071A2 (en) 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
WO2011047180A1 (en) 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
GB2488077A (en) 2009-10-30 2012-08-15 Novozymes Biopharma Dk As Albumin variants
WO2012078153A1 (en) 2010-12-08 2012-06-14 Viacyte, Inc. Agents and methods for inhibiting human pluripotent stem cell growth
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013086786A1 (zh) 2011-12-15 2013-06-20 Qin Shulin 具有降血糖作用的化合物、组合物及其用途
WO2014052451A2 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
KR20150134417A (ko) 2013-03-29 2015-12-01 메리맥 파마슈티컬즈, 인크. 연골-결합 융합 단백질
AU2015204540B2 (en) 2014-01-12 2020-03-19 Igf Oncology, Llc Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
EP3355907B1 (en) 2015-10-02 2021-01-20 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526233A (ja) 2005-01-07 2008-07-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−ｉ融合ポリペプチドの組み合わせ治療用物質による肥満治療法
JP2013530146A (ja) 2010-05-21 2013-07-25 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022002528A (ja) * 2015-10-02 2022-01-11 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッドSilver Creek Pharmaceuticals, Inc. 組織修復のための二重特異性治療用タンパク質
JP7365715B2 (ja) 2015-10-02 2023-10-20 シルバー・クリーク・ファーマシューティカルズ・インコーポレイテッド 組織修復のための二重特異性治療用タンパク質

Also Published As

Publication number Publication date
US20190169258A1 (en) 2019-06-06
US12122819B2 (en) 2024-10-22
US11879002B2 (en) 2024-01-23
WO2017059231A1 (en) 2017-04-06
JP2018538356A (ja) 2018-12-27
US11155593B2 (en) 2021-10-26
ES2863278T3 (es) 2021-10-11
EP3355907A4 (en) 2019-08-07
HK1258376A1 (en) 2019-11-08
US20170096469A1 (en) 2017-04-06
CA3000742A1 (en) 2017-04-06
US20200207826A1 (en) 2020-07-02
JP7365715B2 (ja) 2023-10-20
US20250145682A1 (en) 2025-05-08
JP2022002528A (ja) 2022-01-11
US10040840B2 (en) 2018-08-07
US20220162283A1 (en) 2022-05-26
EP3355907A1 (en) 2018-08-08
EP3865147A1 (en) 2021-08-18
CN108367048A (zh) 2018-08-03
CN108367048B (zh) 2022-08-12
EP3865147B1 (en) 2025-08-27
CN115960249A (zh) 2023-04-14
US20220009991A1 (en) 2022-01-13
EP3355907B1 (en) 2021-01-20
US10633425B2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
JP7005019B2 (ja) 組織修復のための二重特異性治療用タンパク質
JP6822911B2 (ja) 二重特異的融合タンパク質
JP6809789B2 (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
JPWO2018079702A1 (ja) ラクトフェリン／アルブミン融合タンパク質及びその製造方法
CN105524176B (zh) 双特异性融合蛋白
TW201107471A (en) Polypeptides selective for αvβ3 integrin conjugated with a variant of human serum albumin (HSA) and pharmaceutical uses thereof
EP3315515A1 (en) Fusion protein containing bdnf
AU2006237613A1 (en) Q3 SPARC deletion mutant and uses thereof
CN107427574A (zh) Cxcr4结合分子
CN107810195B (zh) 重组丛生蛋白及其在疾病治疗和预防中的应用
JP2018529729A (ja) 胆汁酸障害の処置
HK40058660A (en) Bi-specific therapeutic proteins for tissue repair
HK1258376B (en) Bi-specific therapeutic proteins for tissue repair
CN110639012A (zh) 一种能有效治疗和/或预防1型糖尿病的dna疫苗及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210929

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210929

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211012

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211102

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211207

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211223

R150 Certificate of patent or registration of utility model

Ref document number: 7005019

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250